News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Analyst says Blue Owl (OWL) is overvalued given near-term risks.
  • Analyst recommends a tactical short on OWL with entry $10.03, target $8.00, stop $11.00.
  • Rising short interest is cited as a catalyst adding pressure to OWL shares.
  • Legal inquiries into Blue Owl's legacy vehicles increase regulatory risk for the firm.
  • Leader's Advantage Acquisition Corp. raised $150 million by selling 15 million units at $10 each.
  • The SPAC's units began trading on Nasdaq under ticker LEDRU.
  • The blank-check company will pursue a healthcare-related acquisition, including pharmaceuticals or specialty chemicals.

Latest Articles

AIHS and CECC Form Joint Venture to Develop, Invest In, Construct and Operate AI Data Centers in the United States

AIHS and CECC Form Joint Venture to Develop, Invest In, Construct and Operate AI Data Centers in the United States

Senmiao Technology Limited (Nasdaq: AIHS) announced a joint venture with Constant Energy Construction Corp. to develop, invest in, construct, and operate AI data centers across the United States. This strategic move marks AIHS's expansion into the digital infrastructure sector, leveraging CECC's energy infrastructure and construction expertise alon…

Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering

Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering

Iridex Corporation announced the addition of its EndoProbe® Handpieces to the EyeProGPO product offering, making these disposable laser delivery devices available at preferred pricing to more than 4,300 EyeProGPO members. This expansion strengthens Iridex's collaboration with EyeProGPO and enhances ophthalmology practices' access to innovative reti…

NN, Inc. Expands Contract Manufacturing of Weapons Components, Secures New Awards with Leading Firearms Provider

NN, Inc. Expands Contract Manufacturing of Weapons Components, Secures New Awards with Leading Firearms Provider

NN, Inc. has successfully entered the US Tier 1 contract manufacturing market for firearm components, securing a multi-million dollar contract with a leading firearms provider. This new venture, part of NN's Defense & Electronics growth strategy, is expected to generate $12-15 million in sales starting Q3 2026 and ramp through 2028. The company's e…

Seer Urges Stockholders to Vote “FOR” Seer’s Highly Qualified Director Nominees on the BLUE Proxy Card TODAY

Seer Urges Stockholders to Vote “FOR” Seer’s Highly Qualified Director Nominees on the BLUE Proxy Card TODAY

Seer, Inc. is urging its shareholders to vote in favor of its board nominees ahead of the 2026 Annual Meeting, emphasizing the strong qualifications and independence of its directors. The company is countering a proxy challenge from activists seeking to replace several directors with candidates lacking proteomics and life sciences experience, which…

Nephros to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET

Nephros to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET

Nephros, Inc., a water technology company specializing in filtration solutions, announced that its CEO Robert Banks will present at the 'Health, Wellness & Longevity' virtual conference hosted by Maxim Group. The conference focuses on innovations in consumer health sectors including beverages, food, supplements, and longevity.

INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform

INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform

INmune Bio Inc. has successfully completed the transfer of its mesenchymal stromal cell manufacturing process to a commercial-ready stage, meeting MHRA, EMA, and FDA standards. This milestone supports the planned Phase 3 confirmation trial of its product Ebstrocel™, derived from the CORDStrom™ platform for treating recessive dystrophic epidermolysi…

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

Harrow, a Nasdaq-listed ophthalmic disease management company, announced the presentation of three studies at the ASRS 2026 Annual Meeting that support its ocular anesthetic IHEEZO and biosimilar BYOOVIZ. Early data suggest IHEEZO improves patient experience with less pain and no increased risk of infection. Ongoing QUELL trial enrollment aims to p…

USA Rare Earth Announces Leadership Transition

USA Rare Earth Announces Leadership Transition

USA Rare Earth announces planned retirement of CEO Barbara Humpton effective October 1, 2026, with Thras Moraitis set to succeed her following the anticipated completion of the merger with Serra Verde by end of August 2026. Michael Blitzer appointed Executive Chairman immediately. The leadership change marks a shift from strategic buildup to operat…

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology

Can-Fite BioPharma announced that positive Phase 2a clinical trial results of Namodenoson in advanced pancreatic ductal adenocarcinoma (PDAC) have been accepted for presentation at the prestigious ESMO Congress 2026. The study demonstrated durable disease stabilization and encouraging survival outcomes in a difficult-to-treat patient population, me…

OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans

OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans

OKYO Pharma has filed its Annual Report for fiscal year ending March 31, 2026, announcing a robust cash position following a $25 million capital raise. The funds will support the commencement and completion of the FDA-agreed global Phase 3 NEPTUNE trial for its lead drug candidate urcosimod, aimed at treating neuropathic corneal pain. Positive FDA …

Buy the Dip in CoreWeave - A Tactical, Capacity-Driven Long

Buy the Dip in CoreWeave - A Tactical, Capacity-Driven Long

CoreWeave is a pure-play GPU cloud provider positioned to capture outsized demand from generative AI workloads. We view recent weakness as a tactical buying opportunity: the company benefits from structural capacity tightness, enterprise GPU migration, and favorable contract structures. Our trade plan offers an entry at $50.00, a $80.00 target and …

GE Aerospace Partners with NASA, BETA Technologies, and Boeing on World’s First High-Altitude Hybrid Electric Flight

GE Aerospace Partners with NASA, BETA Technologies, and Boeing on World’s First High-Altitude Hybrid Electric Flight

GE Aerospace announced a groundbreaking achievement in hybrid electric aviation by successfully conducting the world's first high-altitude hybrid electric flight above 30,000 feet. In collaboration with NASA, BETA Technologies, and Boeing, the flight demonstrated the operational viability and endurance of GE Aerospace's megawatt-class hybrid electr…

Parsons To Modernize New York’s Intelligent Transportation System

Parsons To Modernize New York’s Intelligent Transportation System

Parsons Corporation secured a $33 million contract from the New York State Department of Transportation to deploy its iNET® intelligent transportation software across all 11 districts statewide. This contract includes system design, software development, integration, testing, and ongoing operations and maintenance to enhance traffic management effi…

Buy AleAnna (ANNA): Play Italy’s Gas Rebound with a Disciplined Long

Buy AleAnna (ANNA): Play Italy’s Gas Rebound with a Disciplined Long

AleAnna operates low-carbon natural gas assets in Italy's Po Valley and just received a DeGolyer & MacNaughton report identifying ~520 Bcf net prospective resource plus a production concession for Gradizza. With a market cap near $230M, enterprise value of about $110M and positive cash flow, the stock offers asymmetric upside if European gas prices…

Special Committee of Seer’s Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.

Special Committee of Seer’s Board of Directors Unanimously Rejects Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.

Seer, Inc.'s Special Committee of independent directors thoroughly reviewed an unsolicited acquisition proposal from the company's CEO Omid Farokhzad, M.D. to acquire all Class A shares at $2.45 per share plus contingent value rights. The Committee unanimously rejected the proposal, determining it undervalues Seer and does not fully recognize the c…

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

Greenwich LifeSciences provided clinical updates on their Phase III FLAMINGO-01 trial evaluating GLSI-100, an immunotherapy aimed at preventing breast cancer recurrence. The study received Data Safety Monitoring Board approval to continue without modification, and regulatory agencies have endorsed planned protocol changes including increased study …

Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar

Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar

Immuron Limited announced that CEO Steven Lydeamore will present at the Kalkine Media Webinar, discussing the company's biopharmaceutical developments, including their oral polyclonal antibody treatments like Travelan® for travelers’ diarrhea, and ongoing research on therapies for Clostridioides difficile and IBS. The presentation highlights Immuro…